{"nctId":"NCT00137111","briefTitle":"Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2000-07-08","type":"ACTUAL"},"conditions":["Lymphoblastic Leukemia, Acute"],"count":501,"armGroups":[{"label":"1","type":"OTHER","interventionNames":["Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin","Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase","Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide","Drug: Mercaptopurine, Imatinib","Procedure: chemotherapy, intrathecal chemotherapy","Procedure: steroid therapy, hematopoietic stem cell transplantation"]},{"label":"2","type":"OTHER","interventionNames":["Drug: Prednisone, Dexamethasone, Vincristine, Daunorubicin","Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase","Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide","Drug: Mercaptopurine, Imatinib","Procedure: chemotherapy, intrathecal chemotherapy","Procedure: steroid therapy, hematopoietic stem cell transplantation"]}],"interventions":[{"name":"Prednisone, Dexamethasone, Vincristine, Daunorubicin","otherNames":[]},{"name":"Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase","otherNames":[]},{"name":"Methotrexate, Cyclophosphamide, Cytarabine, Etoposide","otherNames":[]},{"name":"Mercaptopurine, Imatinib","otherNames":[]},{"name":"chemotherapy, intrathecal chemotherapy","otherNames":[]},{"name":"steroid therapy, hematopoietic stem cell transplantation","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of non-B-cell ALL by immunophenotyping, as determined by the reactivity pattern to a panel of monoclonal antibodies with flow cytometry as well as morphology and cytochemical staining.\n* Age range: 1 to 18 years (inclusive).\n\nExclusion Criteria:\n\nâ€¢ Previously treated with chemotherapy for one week or longer.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Months","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Event-free Survival (EFS)","description":"EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Continuous Complete Remission Since Week 56 Therapy.","description":"CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Minimal Residual Disease (MRD)","description":"Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (\\>=0.01%).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"390","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).","description":"Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m\\^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1688","spread":"2015"},{"groupId":"OG001","value":"2521","spread":"2950"}]}]}]},{"type":"SECONDARY","title":"Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)","description":"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count\n\nMeasurement: Percentage change of leukemia cells from baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44","spread":"42.2"},{"groupId":"OG001","value":"-50","spread":"35.5"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells","description":"Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"341.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"447.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells","description":"Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"110.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":74,"n":498},"commonTop":["Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infe","Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia","Infection without neutropenia","Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)","Catheter-related infection"]}}}